*Deaths with confirmed or presumed COVID-19, pneumonia, or influenza, coded to ICD-10 codes U07.1 or J09-J18.9.
†RESP-NET conducts surveillance for laboratory-confirmed hospitalizations of COVID-19 (COVID-NET), influenza (FluSurv-NET), and RSV (RSV-NET). Rates presented capture cumulative figures for COVID-19 and influenza-associated hospitalizations and were not adjusted for testing practices, which may differ by pathogen, age, race/ethnicity, and other demographic criteria.
People aged ≥65 years accounted for ~63% of COVID-19–associated hospitalizations and ~88% of COVID-19– associated in-hospital deaths.7,‡
‡Data from January 2023 to August 2023.
Source: CDC. COVID-NET conducts population-based surveillance for laboratory-confirmed COVID-19–associated hospitalizations across 13 US states.
Among 540,667 adult patients hospitalized with COVID-19, a study found the following select comorbidities to be risk factors for progression to severe COVID-19, including death:
Comorbidities | Death Risk Ratio Increase | aRR (95% CI) |
---|---|---|
Obesity | 30% | 1.30 (1.27 to 1.33) |
Diabetes with complications | 26% | 1.26 (1.24 to 1.28) |
Chronic kidney disease | 21% | 1.21 (1.19 to 1.24) |
COPD and bronchiectasis | 18% | 1.18 (1.16 to 1.20) |
Neurocognitive disorders | 18% | 1.18 (1.15 to 1.21) |
CAD and other heart disease | 14% | 1.14 (1.12 to 1.16) |
Source: CDC; Premier Healthcare Database, Special COVID-19 Release, March 2020–March 2021.
Source: CDC; Premier Healthcare Database, Special COVID-19 Release, March 2020–March 2021.
Premier, Inc., and HealthVerity, Inc.; 01/2023 to 01/2025.
Patients with any degree of renal impairment, including those on dialysis
Patients with any stage of hepatic impairment
Pregnant or breastfeeding patients
Pediatric patients as early as birth to <18 years of age weighing at least 1.5 kg
See how COVID-19 continues to be a public health concern
Tap for Important Safety Information, including contraindication for history of clinically significant hypersensitivity to VEKLURY.
VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg), who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
Contraindication
Warnings and precautions
Adverse reactions
Dosage and administration
Pregnancy and lactation
VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg), who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
Please see full Prescribing Information for VEKLURY.
aRR=adjusted risk ratio; CAD=coronary atherosclerosis disease; COPD=chronic obstructive pulmonary disease; ICD-10=International Classification of Diseases, 10th Revision.